GlassScriptPhysician profile
George A Poulos
NPI 1548469091
$2,035.00
in general payments reported to CMS, 2019-2025
21 companies · $381 in 2025
The $381 reported for 2025 was more than what a typical Otolaryngology/Facial Plastic Surgery provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $207 · 2020: $29.50 · 2022: $336 · 2023: $381 · 2024: $701 · 2025: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,462.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $391.30 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $325.51 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $253.91 | 2022-2024 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $238.25 | 2022-2023 | |
| Aerin Medical INC. | $145.77 | 2024 | |
| Kaleo, INC. | $138.15 | 2019-2024 | Auvi-Q |
| Hikma Pharmaceuticals USA | $89.97 | 2023-2024 | Ryaltris |
| Ars Pharmaceuticals Operations, INC. | $79.31 | 2025 | Neffy |
| Neurent Medical Limited | $56.18 | 2024 | Neuromark Device, Neuromark Radiofrequency Console |
| Medtronic, INC. | $55.94 | 2024 | Propel |
| Amgen INC. | $49.67 | 2022-2025 | Tezspire |
| Intersect Ent, INC. | $42.24 | 2019 | |
| Stryker Corporation | $38.95 | 2019 | |
| Smith+Nephew, INC. | $24.89 | 2019 | |
| Genentech USA, INC. | $20.17 | 2025 | Xolair |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $16.36 | 2023 | |
| Incyte Corporation | $15.33 | 2025 | Opzelura |
| Kowa Pharmaceuticals America, INC. | $14.44 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.06 | 2019 | |
| Mylan Pharmaceuticals INC. | $13.60 | 2020 | |
| Glenmark Therapeutics INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Poulos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.